The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Tranylcypromine in mind (Part I): Review of pharmacology
Open accessAbstract
It has been over 50 years since a review has focused exclusively on the monoamine oxidase (MAO) inhibitor tranylcypromine (TCP). A new review has therefore been conducted for TCP in two parts which are written to be read preferably in close conjunction: Part I – pharmacodynamics, pharmacokinetics, drug interactions, toxicology; and Part II – clinical studies with meta-analysis of controlled studies in depression, practice of TCP treatment, place in therapy. Pharmacological data of this review part I characterize TCP as an irreversible and nonselective MAO-A/B inhibitor at low therapeutic doses of 20 mg/day with supplementary norepinephrine reuptake inhibition at higher doses of 40–60 mg/day. Serotonin, norepinephrine, dopamine, and trace amines, such as the “endogenous amphetamine” phenylethylamine, are increased in brain, which leads to changes in neuroplasticity by e.g. increased neurotrophic growth factors and translates to reduced stress-induced hypersecretion of corticotropin releasing factor (CRF) and positive testing in animal studies of depression. TCP has a pharmacokinetic half-life ( t 1/2 ) of only 2 h which is considerably lower than for most other antidepressant drugs. However, a very long pharmacodynamic half-life of about one week is found because of the irreversible MAO inhibition. New studies show that, except for cytochrome P450 (CYP) 2A6, no other drug metabolizing CYP-enzymes are inhibited by TCP at therapeutic doses which defines a low potential of pharmacokinetic interactions in the direction from TCP to other drugs. Insufficient information is available, however, for plasma concentrations of TCP influenced by comedication. More quantitative data are also needed for TCP metabolites such as p-hydroxytranylcypromine and N-acetyltranylcypromine. Pharmacodynamic drug interactions comprise for instance severe serotonin toxicity (SST) with serotonergic drugs and hypertensive crisis with indirect sympathomimetics. Because of the risk of severe food interaction, TCP treatment remains beset with the need for a mandatory tyramine-restricted diet. Toxicity in overdose is similar to amitriptyline and imipramine according to the distance of therapeutic to toxic doses. In conclusion, TCP is characterized by an exceptional pharmacology which is different to most other antidepressant drugs, and a more special evaluation of clinical efficacy and safety may therefore be needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., Klein, H.-U., Popescu, A. C., Burnett, A., Mills, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2661 · Cited by 672
Monoamine oxidase inactivation: from pathophysiology to therapeutics
Bortolato, M., Chen, K., & Shih, J. C. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.06.002 · Cited by 634
Meyer, J. H., Ginovart, N., Boovariwala, A., Sagrati, S., Hussey, D., Garcia, A., Young, T., Praschak-Rieder, N., Wilson, A. A., & Houle, S. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1209 · Cited by 585
Tranylcypromine versus imipramine in anergic bipolar depression
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.7.910 · Cited by 360
Dias, B. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00198-9 · Cited by 274
Meyer, J. H., Wilson, A. A., Sagrati, S., Miler, L., Rusjan, P., Bloomfield, P. M., Clark, M., Sacher, J., Voineskos, A. N., & Houle, S. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.156 · Cited by 182
Selective Norepinephrine Reuptake Inhibition as a Human Model of Orthostatic Intolerance
Schroeder, C., Tank, J., Boschmann, M., Diedrich, A., Sharma, A. M., Biaggioni, I., Luft, F. C., & Jordan, J. (2002) · Circulation · doi:10.1161/hc0302.102597 · Cited by 127
Stout, S. C., Owens, M. J., & Nemeroff, C. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1085 · Cited by 117
Thomas, S. J., Shin, M., McInnis, M. G., & Bostwick, J. R. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1576 · Cited by 116
Monoamine oxidase inhibitors in resistant major depression
Nolen, W. A., Haffmans, P. M. J., Bouvy, P. F., & Duivenvoorden, H. J. (1993) · Journal of Affective Disorders · doi:10.1016/0165-0327(93)90104-r · Cited by 56
Cited by
LSD1/KDM1A inhibitors in clinical trials: advances and prospects
Fang, Y., Liao, G., & Yu, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0811-9 · Cited by 438
Gillman, P. K. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1932-y · Cited by 255
Suchting, R., Tirumalaraju, V., Gareeb, R., Bockmann, T., de Dios, C., Aickareth, J., Pinjari, O., Soares, J. C., Cowen, P. J., & Selvaraj, S. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.01.021 · Cited by 73
Metadata
- Authors
- Ulrich, S., Ricken, R., & Adli, M.
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 27
- Issue
- 8
- Pages
- 697-713
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W2664858983
- Cited by
- 237
- References
- 11
- FWCI
- 29.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tranylcypromine in mind (Part I): Review of pharmacology. https://app.cochat.ai/papers/10.1016/j.euroneuro.2017.05.007
- The paper
- Ulrich, S., Ricken, R., & Adli, M. (2017). Tranylcypromine in mind (Part I): Review of pharmacology. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2017.05.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.